SREBP-1 and fatty liver. Clinical relevance for diabetes, obesity, dyslipidemia and atherosclerosis [SREBP-1 und Fettleber: Klinische Bedeutung für Diabetes, Adipositas, Dyslipidämie und Atherosklerose]

被引：2
作者：
Müller-Wieland D. [1 ]
Knebel B. [2 ]
Haas J. [1 ]
Kotzka J. [2 ]
机构：
[1] Erz-Gefäß-und Diabeteszentrum, Abteilung für Allgemeine Innere Medizin, Semmelweis-Universität, Lohmühlenstr. 5
[2] Institut für Klinische Biochemie und Pathobiochemie, Deutsches Diabetes-Zentrum, Heinrich-Heine-Universität, Düsseldorf
来源：
Herz | 2012年 / 37卷 / 3期
关键词：
Fatty liverNon-alcoholic fatty liver disease; Insulin resistance; Metabolic syndrome; Obesity;
D O I：
10.1007/s00059-012-3608-y
中图分类号：
学科分类号：
摘要：
AbstractInsulin resistance and visceral fat distribution usually play a major role in the development of clinical aspects of the metabolic syndrome, such as dyslipidemia, diabetes and atherosclerosis. In this review, the focus will be on some novel relationships with a fatty liver, for which susceptibility appears to be mediated by the activity of transcription factors, such as sterol regulatory element-binding protein 1 (SREBP-1). In addition to this molecular aspect therapeutic life-style modifications, such as weight reduction which are associated with increased insulin sensitivity and a decrease of fat in the liver will be discussed © 2012 Urban & Vogel.
引用
收藏
页码：273 / 280
页数：7
相关论文
共 41 条
  • [1] Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., Franklin, B.A., Gordon, D.J., Costa, F., Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement (2005) Circulation, 112 (17), pp. 2735-2752. , DOI 10.1161/CIRCULATIONAHA.105.169404
  • [2] Alberti, K.G., Eckel, R.H., Grundy, S.M., Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention (2009) Circulation, 120, pp. 1640-1645. , National Heart, Lung, and Blood Institute
  • [3] American Heart Association
  • [4] World Heart Federation
  • [5] International Atherosclerosis Society
  • [6] and International Association for the Study of Obesity
  • [7] Ludwig, J., Viggiano, T.R., McGill, D.B., Ott, B.J., Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease (1980) Mayo Clinic Proceedings, 55 (7), pp. 434-438
  • [8] Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease (2005) Journal of Clinical Investigation, 115 (5), pp. 1343-1351. , DOI 10.1172/JCI200523621
  • [9] Day, C.P., James, O.F., Steatohepatitis: A tale of two "hits"? (1998) Gastroenterology, 114, pp. 842-845
  • [10] Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Rizzetto, M., Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome (2003) Hepatology, 37 (4), pp. 917-923. , DOI 10.1053/jhep.2003.50161
12345